EGFR-induced phosphorylation of type Iγ phosphatidylinositol phosphate kinase promotes pancreatic cancer progression
暂无分享,去创建一个
Kun Ling | Jue-min Fang | Jinghua Hu | Yan Huang | Kun Ling | Chunhua Chen | Xiangling Wang | Juemin Fang | Junli Xue | Xunhao Xiong | Jinghua Hu | Xunhao Xiong | Yan Huang | Junli Xue | Chunhua Chen | Xiangling Wang
[1] Suyong Choi,et al. Phosphatidylinositol Phosphate 5-Kinase Iγ and Phosphoinositide 3-Kinase/Akt Signaling Couple to Promote Oncogenic Growth* , 2015, Journal of Biological Chemistry.
[2] Yue Sun,et al. Prospects & Overviews Phosphatidylinositol 4,5-bisphosphate: Targeted Production and Signaling , 2022 .
[3] L. Traub,et al. Clathrin Regulates the Association of PIPKIγ661 with the AP-2 Adaptor β2 Appendage* , 2009, Journal of Biological Chemistry.
[4] Shizuo Akira,et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.
[5] P. Philip,et al. Targeting Epidermal Growth Factor Receptor–Related Signaling Pathways in Pancreatic Cancer , 2015, Pancreas.
[6] Yue Sun,et al. Type Iγ phosphatidylinositol phosphate kinase is required for EGF-stimulated directional cell migration , 2007, The Journal of cell biology.
[7] M. Karin,et al. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. , 2011, Cancer Cell.
[8] Stephen J. Weiss,et al. Regulation of Cell Invasion and Morphogenesis in a Three-Dimensional Type I Collagen Matrix by Membrane-Type Matrix Metalloproteinases 1, 2, and 3 , 2000, The Journal of cell biology.
[9] V. Haucke,et al. Stimulation of phosphatidylinositol kinase type I-mediated phosphatidylinositol (4,5)-bisphosphate synthesis by AP-2μ–cargo complexes , 2006, Proceedings of the National Academy of Sciences.
[10] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[11] Yue Sun,et al. Movin' on up: the role of PtdIns(4,5)P(2) in cell migration. , 2006, Trends in cell biology.
[12] O. Rath,et al. MAP kinase signalling pathways in cancer , 2007, Oncogene.
[13] N. Jamieson,et al. Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma , 2013, Journal of Gastrointestinal Surgery.
[14] Pietro De Camilli,et al. Recruitment and regulation of phosphatidylinositol phosphate kinase type 1γ by the FERM domain of talin , 2002, Nature.
[15] Alex J. Walsh,et al. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. , 2015, Gastroenterology.
[16] D. Mosher,et al. Tyrosine phosphorylation of type Iγ phosphatidylinositol phosphate kinase by Src regulates an integrin–talin switch , 2003, The Journal of cell biology.
[17] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[18] A. Jemal,et al. Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.
[19] J. Keski‐Oja,et al. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. , 1998, The Biochemical journal.
[20] H. Sato,et al. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. , 1996, Cancer research.
[21] P. De Camilli,et al. ARF6 stimulates clathrin/AP-2 recruitment to synaptic membranes by activating phosphatidylinositol phosphate kinase type Iγ , 2003, The Journal of cell biology.
[22] Qingwen Xu,et al. PIPKI&ggr; targets to the centrosome and restrains centriole duplication , 2014, Journal of Cell Science.
[23] H. Fölsch. Faculty Opinions recommendation of Type I gamma phosphatidylinositol phosphate kinase modulates adherens junction and E-cadherin trafficking via a direct interaction with mu 1B adaptin. , 2007 .
[24] Wei Guo,et al. Phosphatidylinositol 4,5-bisphosphate mediates the targeting of the exocyst to the plasma membrane for exocytosis in mammalian cells. , 2007, Molecular biology of the cell.
[25] Y. Soini,et al. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] J. Darnell,et al. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.
[27] K. Hirata,et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Grandis,et al. STAT3 signaling: anticancer strategies and challenges. , 2011, Molecular interventions.
[29] Delong Liu,et al. Novel agents for advanced pancreatic cancer , 2015, Oncotarget.
[30] F. Ciardiello,et al. Targeting EGFR in pancreatic cancer treatment. , 2012, Current drug targets.
[31] G. Sledge,et al. Coordinated increase in activities of the signal transduction enzymes PI kinase and PIP kinase in human cancer cells. , 1994, Life Science.
[32] Suyong Choi,et al. Isoform 5 of PIPKI&ggr; regulates the endosomal trafficking and degradation of E-cadherin , 2014, Journal of Cell Science.
[33] H. Mori,et al. CD44 directs membrane‐type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin‐like domain , 2002, The EMBO journal.
[34] Jens T Siveke,et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. , 2012, Cancer cell.
[35] M. Fjällskog,et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] S. Leung,et al. Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer , 2010, Breast Cancer Research.
[37] Xiaojing Su,et al. Type Iγ661 Phosphatidylinositol Phosphate Kinase Directly Interacts with AP2 and Regulates Endocytosis* , 2006, Journal of Biological Chemistry.
[38] Xiaojun Tan,et al. Endosomal type Iγ PIP 5-kinase controls EGF receptor lysosomal sorting. , 2013, Developmental cell.
[39] J. Dagorn,et al. A Review of Kinases Implicated in Pancreatic Cancer , 2010, Pancreatology.
[40] K. Ling,et al. Type I gamma phosphatidylinositol phosphate kinase targets and regulates focal adhesions. , 2002, Nature.
[41] M. Barbacid,et al. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. , 2012, Cancer cell.
[42] S. Akira,et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. , 2011, Cancer cell.
[43] Hua Yu,et al. STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.
[44] R. Anderson,et al. Two novel phosphatidylinositol-4-phosphate 5-kinase type Iγ splice variants expressed in human cells display distinctive cellular targeting , 2009, The Biochemical journal.
[45] W. Rizwani,et al. Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge , 2015, Cancers.
[46] Motoharu Seiki,et al. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. , 2003, Cancer letters.